Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486209 | 1.00 | TYMP (0.52) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL12856853 | 1.00 | TYMP (0.52) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL9913205 | 0.90 | TYMP (0.51) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL9548812 | 0.90 | ALDH1A1 (0.55) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL1514931 | 0.86 | POLB (0.51) | STING1GSK3ARPS6KA3MAPK14P2RY1 | |
| SCHEMBL12570242 | 0.86 | POLB (0.51) | STING1GSK3ARPS6KA3MAPK14P2RY1 | |
| SCHEMBL7613803 | 0.86 | POLB (0.51) | STING1GSK3ARPS6KA3MAPK14P2RY1 | |
| SCHEMBL11986893 | 0.83 | POLB (0.47) | ALDH1A1MAPK1STING1P2RY1 | |
| SCHEMBL7215063 | 0.83 | POLB (0.47) | ALDH1A1MAPK1STING1P2RY1 | |
| SCHEMBL21317437 | 0.83 | POLB (0.47) | ALDH1A1MAPK1STING1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230175030-A1 | NUCLEIC ACID POLYMER WITH AMINE-MASKED BASES | Nuclera Nucleics Ltd. (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20230175030-A1 | NUCLEIC ACID POLYMER WITH AMINE-MASKED BASES | Nuclera Nucleics Ltd. (GB) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230175030-A1 | NUCLEIC ACID POLYMER WITH AMINE-MASKED BASES | RNGTT, POLM, POLRMT | TYMP 71/4885ALDH1A1 1649/4885LMNA 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.